Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney

di Heerspink, Hiddo J L
Pubblicato in Nephrol Dial Transplant (2019)

Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease: Moving from Single Trials to an Ongoing Platform

di Heerspink, Hiddo J.L., Perkovic, Vlado
Pubblicato in Clin J Am Soc Nephrol (2018)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease

di Heerspink, Hiddo J. L., De Zeeuw, Dick
Pubblicato in Diabetologia (2016)

Treating diabetic complications; from large randomized clinical trials to precision medicine

di Heerspink, Hiddo J. L., de Zeeuw, Dick
Pubblicato in Diabetes Obes Metab (2018)

Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy

di de Zeeuw, Dick, Heerspink, Hiddo J L
Pubblicato in Nephrol Dial Transplant (2020)

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era

di Heerspink, Hiddo J. L., List, James, Perkovic, Vlado
Pubblicato in Diabetes Obes Metab (2018)

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease

di Heerspink, Hiddo J L, Fouque, Denis, Wanner, Christoph
Pubblicato in Nephrol Dial Transplant (2020)

Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease

di Pena, Michelle J., Mischak, Harald, Heerspink, Hiddo J. L.
Pubblicato in Diabetologia (2016)

ACCORDION: Ensuring That We Hear the Music Clearly

di Wong, Muh Geot, Heerspink, Hiddo J.L., Perkovic, Vlado
Pubblicato in Clin J Am Soc Nephrol (2018)

Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials

di Koomen, Jeroen V., Stevens, Jasper, Heerspink, Hiddo J.L.
Pubblicato in Br J Clin Pharmacol (2020)

Precision medicine approaches for diabetic kidney disease: opportunities and challenges

di Tye, Sok Cin, Denig, Petra, Heerspink, Hiddo J L
Pubblicato in Nephrol Dial Transplant (2021)

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors

di Dekkers, Claire C. J., Gansevoort, Ron T., Heerspink, Hiddo J. L.
Pubblicato in Curr Diab Rep (2018)

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?

di Perco, Paul, Pena, Michelle, Heerspink, Hiddo J.L., Mayer, Gert
Pubblicato in Kidney Int Rep (2018)

Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus

di Vinke, Joanna Sophia J., Heerspink, Hiddo J.L., de Borst, Martin H.
Pubblicato in Curr Opin Nephrol Hypertens (2019)

No significant association of type 2 diabetes‐related genetic risk scores with glycated haemoglobin levels after initiating metformin or sulphonylurea derivatives

di Martono, Doti P., Heerspink, Hiddo J.L., Hak, Eelko, Denig, Petra, Wilffert, Bob
Pubblicato in Diabetes Obes Metab (2019)

Blood pressure‐lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies

di Olde Engberink, Rik H. G., Heerspink, Hiddo J. L., de Zeeuw, Dick, Vogt, Liffert
Pubblicato in Br J Clin Pharmacol (2016)

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects

di Heerspink, Hiddo J. L., Desai, Mehul, Jardine, Meg, Balis, Dainius, Meininger, Gary, Perkovic, Vlado
Pubblicato in J Am Soc Nephrol (2017)

Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?

di Weldegiorgis, Misghina, de Zeeuw, Dick, Dwyer, Jamie P., Mol, Peter, Heerspink, Hiddo J.L.
Pubblicato in Clin J Am Soc Nephrol (2017)

Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations

di Mol, Peter G. M., Thompson, Aliza, Heerspink, Hiddo J. L., Leufkens, Hubert G. M.
Pubblicato in Diabetes Obes Metab (2018)

Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin

di Kroonen, Marjolein Y. A. M., Stevens, Jasper, de Zeeuw, Dick, Heerspink, Hiddo J. L.
Pubblicato in Diabetes Obes Metab (2019)